Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691855 | 0.86 | MKNK1 (0.67) | FLT3MAPK1MKNK1 | |
| SCHEMBL4686916 | 0.85 | PAK1 (0.64) | FLT3MAPK1LMNATTBK1HTT | |
| SCHEMBL2343403 | 0.82 | MAPK1 (0.58) | FLT3MAPK1LMNATTBK1SLC29A1 | |
| SCHEMBL4686975 | 0.82 | PAK1 (0.62) | FLT3MAPK1HTTMKNK1 | |
| SCHEMBL4690820 | 0.82 | LMNA (0.66) | FLT3MAPK1ADORA3LMNAROCK2 | |
| SCHEMBL4686832 | 0.82 | PTK2 (0.68) | FLT3MAPK1LMNAHTTMKNK1 | |
| SCHEMBL17229965 | 0.80 | FLT3 (1.00) | FLT3 | |
| SCHEMBL26784629 | 0.80 | MAPK1 (0.71) | FLT3MAPK1TTBK1HTTMKNK1 | |
| SCHEMBL1406620 | 0.79 | MAPK1 (1.00) | FLT3MAPK1LMNATTBK1ROCK1 | |
| SCHEMBL26785933 | 0.78 | MAPK1 (0.69) | FLT3MAPK1TTBK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1360582-A | Quinazoline derivs. | ASTRAZENECA UK LTD (GB) | 2002-07-24 | — | — | CN | claimed |
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| CN-1360582-A | Quinazoline derivs. | ASTRAZENECA UK LTD (GB) | 2002-07-24 | — | — | CN | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |